Newer confirmatory tests such as reverse transcription-quenching loop-mediated isothermal amplification12 and anti-promyelocytic leukemia (anti-PML) antibody13,14 have been described, but are not widely used, validated, or incorporated into clinical workflows especially outside of developed countries and tertiary-care centers. The gene discussed is PML; the disease is acute promyelocytic leukemia.